OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Antimicrobial Chemotherapy is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
ResFinder 4.0 for predictions of phenotypes from genotypes	1581
Detection of mobile genetic elements associated with antibiotic resistance in Salmonella enterica using a newly developed web tool: MobileElementFinder	288
COVID-19 and the potential long-term impact on antimicrobial resistance	227
Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey	172
Epidemiology of mobile colistin resistance genes mcr-1 to mcr-9	161
Systematic review of mutations associated with resistance to the new and repurposedMycobacterium tuberculosisdrugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid	125
The global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli in the community	113
Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study	103
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis	96
Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19	88
Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	85
Impact of the COVID-19 pandemic on the surveillance, prevention and control of antimicrobial resistance: a global survey	84
EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories	82
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study	82
Implications of antibiotics use during the COVID-19 pandemic: present and future	82
Favipiravir, an antiviral for COVID-19?	77
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	72
An observational cohort study of bacterial co-infection and implications for empirical antibiotic therapy in patients presenting with COVID-19 to hospitals in North West London	71
Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola viru	69
Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomize	64
Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review	62
Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries	58
Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials	57
Carbapenemase-producing Enterobacterales causing secondary infections during the COVID-19 crisis at a New York City hospital	55
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19	54

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study	51
Lopinavir pharmacokinetics in COVID-19 patients	50
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection	48
Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections	45
Early therapeutic monitoring of β-lactams and associated therapy outcomes in critically ill patients	44
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect	44
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii	43
Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it	43
Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge	43
The changing epidemiology of carbapenemase-producingKlebsiella pneumoniaein Italy: toward polyclonal evolution with emergence of high-risk lineages	43
Oxazolidinones: mechanisms of resistance and mobile genetic elements involved	42
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial	41
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU	39